Dr. Fowler on the Mechanism of Action of T-rapa Cells

Daniel H. Fowler, MD
Published Online: Tuesday, June 18, 2013
Daniel H. Fowler, MD, senior investigator, Center for Cancer Research, National Cancer Institute, describes the mechanism of action of T-rapa cells.

In clinical trials, researchers have found that when T cells are incubated ex vivo in rapamycin (an inhibitor of mTOR), instead of dying, T cells can overcome the rapamycin effect and survive the culture system.

In this situation, the cells are being starved ex vivo, but signaling remains to keep them growing and have them emerge as healthy cells. Fowler notes that this process is somewhat paradoxical. Fowler has studied T-rapa cells in a phase II clinical trial after low-intensity allogeneic hematopoietic cell transplantation.
Online CME Activities
Free CME from PER
Advances in ImmunoOncology: Intralesional Oncolytic Immunotherapy in Melanoma
Updates in the Treatment of Lung Cancer
10th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® Medical Crossfire®
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
More Reading
$auto_registration$